In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The Chief Executive Officer of Australian College of Nursing, Adjunct Professor Kylie Ward FACN spoke in depth with Australian Health Journal about:
- The key recommendations in ACN’s pre-budget submission to Federal Government
- The impact of legislation requiring a Registered Nurse (RN) at every residential aged care facility from 1st July 2023
- Why scholarships in nursing leadership are important
- Why ACN has recommended the Government fund 200 Pacific nurses in 15 nations for the online ACN postgraduate certification
- The need for a multi-pronged approach that includes skilled migration in rebuilding the nursing workforce
-
Addressing Pharmacy challenges at home and abroad
Paul Sinclair’s progression through the ranks of the International Pharmaceutical Federation (FIP) demonstrates the impact and influence he’s had in representing the pharmacy profession on a global scale. In this Australian Health Journal interview, Paul talks about the 4 themes in the upcoming FIP Congress in Brisbane this month. He also talks about the challenges facing pharmacy with remuneration, professional service delivery and the workforce coming out of the COVID era.
-
Smarter investment in the research long game
In this Op-Ed, Nadia Levin, CEO of Research Australia, spoke with the Australian Health Journal about the need for smarter and more strategic investment in Australia’s health and medical research sector.
Levin argued that Australia’s approach to health and medical research has been shaped too heavily by short-term political cycles rather than a long-term national vision. She emphasised that meaningful progress in science, innovation, and healthcare requires sustained investment over many years.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
